SIB-Norwegian Version, Validation and Reliability Study

Dementia Clinical Trial

Official title:

Severe Impairment Study - Norwegian Version. A Validation and Reliability Study.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00449384
• Other study ID #: F06002
• Status: Completed
• Phase: N/A
• First received: March 19, 2007
• Last updated: July 2, 2007
• Start date: February 2007
• Est. completion date: May 2007

Study information

• Verified date: July 2007
• Source: Sykehuset Innlandet HF
• Contact: n/a
• Is FDA regulated: No
• Health authority: Norway: Norwegian Social Science Data ServicesNorway:National Committee for Medical and Health Research Ethics
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to validate and to test interrater reliability for the Norwgian version of Severe Impairment Battery (SIB).

Description:

The study will include 60 persons with mild to severe dementia. To test the validation of SIB, we will interview the included persons with Severe Impairment Battery (SIB) and compare the results with Clinical Dementia Rating (CDV)reported by their nurses. To test interrater reliability 30 of the included persons will be interviewed with SIB by two different raters, and the two raters results will be compared.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 59
• Est. completion date: May 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Dementia, mild to severe.

• Nursing Home resident

Exclusion Criteria:

• No ability to write or read.

• Physical handicapped, unable to use hands.

Study Design

Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Dementia
• Diagnostic Tests, Routine

Intervention

Behavioral:
• Diagnostic Screening

Locations

Country	Name	City	State
Norway	Sykehuset Innlandet HF - Sanderud	Ottestad	Oppland

Sponsors (1)

Lead Sponsor	Collaborator
Sykehuset Innlandet HF

Country where clinical trial is conducted

Norway,